Sirolimus conversion for renal preservation in liver transplantation: Not so fast

Liver Transplantation

Volumn 14, Issue 5, 2008, Pages 601-603

  Jensen, Geoffrey S ^a   Wiseman, Alexander ^a   Trotter, James F ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RAPAMYCIN;

CLINICAL TRIAL; CREATININE CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY PRESERVATION; LIVER TRANSPLANTATION; LOW DRUG DOSE; NEPHROTOXICITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; TREATMENT DURATION;

ANTIMETABOLITES; CALCINEURIN; CREATININE; CYCLOSPORINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; SIROLIMUS; TACROLIMUS; TREATMENT OUTCOME;

EID: 43849107447     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21452     Document Type: Editorial

References (23)

1. Ojo A, Held P, Port F, Wolfe R, Leichtman A, Young E, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-940.
2. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001;72:1934-1939.
3. Campistol JM, Sacks SH. Mechanisms of nephrotoxity. Transplantation 2000;69(suppl 10):S5-S10.
4. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003;35(suppl 3A):7S-14S.
5. Product Information: RapamuneTM (Sirolimus) Oral Solution and Tablets. Philadelphia, PA: Wyeth Laboratories; 2006.
6. Shapiro R, Young JB, Milford EL, Trotter JF, Bustami RT, Leichtman AB. Am J Transpl 2005;5(pt 2):874-886.
7. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003;9:1079-1085.
8. Cotterell AH, Fisher RA, King AL, Gehr TWB, Dawson S, Sterling RK, et al. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunopsuppressive agent. Clin Transplant 2002;16:49-51.
9. Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003;9:126-129.
10. Maheshwari A, Torbenson MS, Thuluvath PJ. Sirolimus monotherapy versus sirolimus in combination with steroids and/or MMF for immunosuppression after liver transplantation. Dig Dis Sci 2006;51:l677-1684.
11. Sanchez EQ, Martin AP, Ikegami T, Uemura T, Narasimhan G, Goldstein RM, et al. Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years. Transplant Proc 2005;37: 4416-4423.
12. Morard I, Dumortier J, Spahr L, Hadengue A, Majno P, Morel P, et al. Conversion to sirolimusr-based immunosuppression in maintenance liver transplantation patients. Liver Transpl 2007;13:658-664.
13. Neff GW, Montalbano M, Slapak-Green G, Meyer D, Berney T, Safdar K, et al. Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. Transplant Proc 2003;35: 3029-3031.
14. Watson CJE, Gimson AES, Alexander GJ, Allison MED, Gibbs P, Smith JC, et al. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to strolimus-based immurrosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2007;13:1694-1702.
15. Shenoy S, Hardinger KL, Crippin J, Desai N, Korenblat K, Lisker-Melman M, et al. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial. Transplantation 2007;83:1389-1392.
16. Campbell MS, Rai J, Kozin E, Bloom RD, Markmann JF, Olthoff KM, et al. Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation. Clin Transplant 2007;21:377-384.
17. Mota A, Arias M, Taskinen EI, Paavonen T, Brault Y, Legendre C, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004;4:953-961.
18. Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 2005;5:1748-1756.
19. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004;4:1869-1875.
20. Wall RK, Mohanlal V, Ramos E, Blahut S, Drachenberg C, Papadimitriou J, et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 2007;7:1572-1583.
21. Schena FP, Wali RK, Pascoe MD, Alberu J, del Carmen Rial M. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 12-month results from a large, randomized, open-label comparative trial. J Am Soc Nephrol 2005;16:32A.
22. Dubay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. Liver Transpl 2008;14:651-659.
23. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 2004;10:301-309.